2016 / 01

Next Paper
DOI: 10.24075/brsmu.2016-01-12

ORIGINAL RESEARCH

Stability of gadolinium-based contrast agents in the presence of zinc and calcium ions in different media

Kharlamov VG1, Kulakov VN2, Lipengolts AA2,3, Shimanovskii NL1
About authors

1 P. V. Sergeev Molecular Pharmacology and Radiobiology Department, Biomedical Faculty,
Pirogov Russian National Research Medical University, Moscow, Russia

2 Laboratory of Radiotherapy Methods and Technologies Development,
A. I. Burnazyan Federal Medical and Biophysical Centre, Moscow, Russia

3 Laboratory of Radionuclide and Radiation Technologies in Experimental Oncology,
N. N. Blokhin Russian Cancer Scientific Centre, Moscow, Russia

Correspondence should be addressed: Nikolay Shimanovskii
ul. Bolshaya Pirogovskaya, d. 9A, Moscow, Russia, 119435; ur.xednay@nnnamihs

About paper

Funding: this study was conducted within the framework of a public contract No. 11411.1008700.13.081 under the Federal Targeted Program “Development of Pharmaceutical and Medical Industries of the Russian Federation up to 2020 and beyond” approved by the resolution of the Government of the Russian Federation No. 91 dated 17 February 2011.

Received: 2015-09-29 Accepted: 2015-10-12 Published online: 2017-01-05
|
  1. Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging. 2012; 36 (5): 1060–71.
  2. Vassallo DV, Simões MR, Furieri LB, Fioresi M, Fiorim J, Almeida EA, et al. Toxic effects of mercury, lead and gadolinium on vascular reactivity. Braz J Med Biol Res. 2011; 44 (9): 939–46.
  3. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006; 17 (9): 2359–62.
  4. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006; 21 (4): 1104–8.
  5. Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology. 2008; 248 (2–3): 77–88.
  6. Radbruch A, Weberling LD, Kieslich PJ, Eidel O, Burth S, Kickingereder P, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015; 275 (3): 783–91.
  7. Robert P, Violas X, Grand S, Lehericy S, Idée JM, Ballet S, et al. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol. 2016; 51 (2): 73–82.
  8. Shimanovskii NL. Kontrastnye sredstva: rukovodstvo po ratsional'nomu primeneniyu. Moscow: GEOTAR-Media; 2009. 464 p. Russian.
  9. Persanova LV, Sdobnova EA, Lysenko AN. Kompleksoobrazuyushchie i dezintoksikatsionnye svoystva infuzionnykh rastvorov na osnove polivinilpirrolidona. Vestnik sluzhby krovi Rossii. 2004; 3: 20–3. Russian.
  10. Laurent S, Elst LV, Copoix F, Muller RN. Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol. 2001; 36 (2): 115–22.
  11. Kuo J, editor. Methods in molecular biology, Vol. 369: Electron microscopy: Methods and protocols. 2nd ed. Totowa, NJ: Humana Press Inc.; 2007.
  12. Taupitz M, Stolzenburg N, Ebert M, Schnorr J, Hauptmann R, Kratz H, et al. Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd(3+) to the glycosaminoglycan heparin. Contrast Media Mol Imaging. 2013; 8 (2): 108–16.
  13. Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, et al. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. Toxicol Sci. 2013; 131 (1): 259–70.
  14. Idée JM, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Crit Rev Toxicol. 2014; 44 (10): 895–913.